- Stereotactic surgery, a form of minimally invasive surgical intervention that uses 3D imaging for precise targeting of anatomical structures, is becoming increasingly critical in the treatment of complex neurological conditions such as brain tumors, epilepsy, Parkinson’s disease, and arteriovenous malformations. Its precision, reduced operative trauma, and shorter recovery times are making it the preferred alternative to traditional open brain surgeries
- The growing demand for stereotactic surgical procedures is primarily driven by the rising global burden of neurological disorders, the increasing availability of advanced imaging and robotic technologies, and a shift towards non-invasive treatment approaches in both developed and emerging healthcare systems
- North America dominates the global stereotactic surgery market, holding the largest revenue share of 41.3% in 2025, owing to robust healthcare infrastructure, early adoption of advanced surgical technologies, and the presence of leading device manufacturers. The U.S. leads the region with a significant number of Gamma Knife and Cyber Knife installations in high-volume hospitals and research institutions
- Asia-Pacific is expected to be the fastest-growing region in the stereotactic surgery market over the forecast period, fueled by a rising patient population, increasing healthcare investments, improving diagnostic infrastructure, and expanding access to advanced neurosurgical procedures in countries like China, India, and Japan
- The Gamma Knife segment is projected to dominate the stereotactic surgery market with a market share of 38.7% in 2025, due to its proven track record in non-invasive treatment of brain lesions and tumors, along with strong clinical efficacy and favorable reimbursement policies in key markets.
